| Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in … E Di Gennaro, M Barbarino, F Bruzzese, S De Lorenzo, M Caraglia, ... Journal of cellular physiology 195 (1), 139-150, 2003 | 183 | 2003 |
| New perspective for an old antidiabetic drug: metformin as anticancer agent A Leone, E Di Gennaro, F Bruzzese, A Avallone, A Budillon Advances in Nutrition and Cancer, 355-376, 2014 | 175 | 2014 |
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT F Bruzzese, A Leone, M Rocco, C Carbone, G Piro, M Caraglia, ... Journal of cellular physiology 226 (9), 2378-2390, 2011 | 155 | 2011 |
| Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15 F Bruzzese, C Hägglöf, A Leone, E Sjöberg, MS Roca, S Kiflemariam, ... Cancer research 74 (13), 3408-3417, 2014 | 136 | 2014 |
| Acetylation of proteins as novel target for antitumor therapy E Di Gennaro, F Bruzzese, M Caraglia, A Abruzzese, A Budillon Amino acids 26, 435-441, 2004 | 120 | 2004 |
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis F Bruzzese, M Rocco, S Castelli, E Di Gennaro, A Desideri, A Budillon Molecular cancer therapeutics 8 (11), 3075-3087, 2009 | 110 | 2009 |
| Targeting mevalonate pathway in cancer treatment: repurposing of statins F Iannelli, R Lombardi, MR Milone, B Pucci, S De Rienzo, A Budillon, ... Recent patents on anti-cancer drug discovery 13 (2), 184-200, 2018 | 102 | 2018 |
| Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation C Ciardiello, A Leone, P Lanuti, MS Roca, T Moccia, VR Minciacchi, ... Journal of Experimental & Clinical Cancer Research 38, 1-16, 2019 | 93 | 2019 |
| Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo F Bruzzese, E Di Gennaro, A Avallone, S Pepe, C Arra, M Caraglia, ... Clinical Cancer Research 12 (2), 617-625, 2006 | 93 | 2006 |
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed E Di Gennaro, F Bruzzese, S Pepe, A Leone, P Delrio, P Subbarayan, ... Cancer biology & therapy 8 (9), 782-791, 2009 | 86 | 2009 |
| Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway A Leone, MS Roca, C Ciardiello, M Terranova-Barberio, C Vitagliano, ... Free Radical Biology and Medicine 89, 287-299, 2015 | 77 | 2015 |
| Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression M Terranova-Barberio, MS Roca, AI Zotti, A Leone, F Bruzzese, ... Oncotarget 7 (7), 7715, 2016 | 70 | 2016 |
| Pathophysiologically relevant in vitro tumor models for drug screening V Das, F Bruzzese, P Konečný, F Iannelli, A Budillon, M Hajduch Drug discovery today 20 (7), 848-855, 2015 | 66 | 2015 |
| Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid V Bizzarro, R Belvedere, MR Milone, B Pucci, R Lombardi, F Bruzzese, ... Oncotarget 6 (28), 25074, 2015 | 62 | 2015 |
| Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial F Caponigro, E Di Gennaro, F Ionna, F Longo, C Aversa, E Pavone, ... BMC cancer 16, 1-10, 2016 | 60 | 2016 |
| Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways F Bruzzese, B Pucci, MR Milone, C Ciardiello, R Franco, MI Chianese, ... Cell death & disease 4 (10), e878-e878, 2013 | 59 | 2013 |
| Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells MR Milone, B Pucci, F Bruzzese, C Carbone, G Piro, S Costantini, ... Cell death & disease 4 (5), e641-e641, 2013 | 58 | 2013 |
| Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents A Budillon, E Di Gennaro, F Bruzzese, M Rocco, G Manzo, M Caraglia Recent patents on anti-cancer drug discovery 2 (2), 119-134, 2007 | 58 | 2007 |
| Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase A Budillon, F Bruzzese, ED Gennaro, M Caraglia Current drug targets 6 (3), 337-351, 2005 | 52 | 2005 |
| Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase E Di Gennaro, G Piro, MI Chianese, R Franco, A Di Cintio, T Moccia, ... British journal of cancer 103 (11), 1680-1691, 2010 | 51 | 2010 |
Alfredo BudillonIstituto Tumori Napoli G. PascaleEmail verificata su istitutotumori.na.it
